Search

everythinglearnresearchcommunity

for

Search:↓

Local hormonal treatment for vulvovaginal atrophy is likely safe for women with estrogen receptor-positive breast cancer on aromatase inhibitors.

Non-hormonal treatments should be used first for sexual dysfunction in postmenopausal breast cancer patients on aromatase inhibitors, with hormones as a second option.

Two teenage boys lost hair after taking a drug for growth, which was not a known side effect for kids.

Exemestane is effective and safe for treating certain breast cancers, with mild side effects, but needs more research on long-term effects.

Topical minoxidil improves hair loss in 80% of women with breast cancer undergoing endocrine therapy.

Hair loss from hormone therapy in breast cancer patients can be improved with minoxidil treatment.

Managing side effects of endocrine therapy is crucial to improve adherence and survival in breast cancer patients.

Certain drugs can worsen hair loss in people prone to androgenetic alopecia.

The medications 5α-reductase inhibitors and spironolactone are generally safe for breast cancer patients on endocrine therapies and do not significantly increase breast cancer risk.

Menopause often leads to lower sexual desire and discomfort during sex, but treatment should be personalized and only if it bothers the woman.

Testosterone replacement therapy helps manage deficiency and has various methods, but requires careful monitoring to avoid side effects.

The document concludes that understanding and managing hair loss in cancer patients is important, and more research is needed for better treatments.

Aromatase inhibitor therapy for breast cancer increases the risk of hair loss and thinning.

Some breast cancer patients on hormone therapy experience hair loss, and treatments like certain topical inhibitors and supplements may help without harming their cancer prognosis.

Intravaginal testosterone cream improves sexual satisfaction and reduces vaginal discomfort in postmenopausal women on breast cancer treatment without affecting hormone levels.

Nutraceuticals that promote hair growth do not reduce tamoxifen's effectiveness in breast cancer treatment.

Hormone therapy for breast cancer often leads to sexual issues like vaginal dryness and decreased libido.

The guidelines advise against using testosterone and DHEA in women for most conditions due to safety and effectiveness concerns, but suggest considering testosterone for postmenopausal women with low sexual desire.

The document concludes that scalp cooling and treatments like minoxidil can help manage hair loss from cancer therapy.

Current treatments for hair loss from chemotherapy are limited, but new methods are being researched.

CDK4/6 inhibitors have improved treatment outcomes for certain advanced breast cancer patients.

Endocrine therapies for cancer significantly increase the risk of hair loss.

The document concludes that various medications and treatments can have significant, sometimes adverse, effects on health outcomes.

Breast cancer patients taking CDK4/6 inhibitors are more likely to experience fatigue, hair loss, and mouth sores.

Scalp cooling is the most effective FDA-approved method to prevent chemotherapy-induced hair loss, but more research is needed for other treatments.

Obstetrician/gynecologists can diagnose and manage female hair loss with careful history taking and examination.

A breast cancer patient had lasting hair loss after chemotherapy, which improved with minoxidil treatment.

Fulvestrant is a well-tolerated new treatment for advanced breast cancer that may delay chemotherapy.

Scalp cooling effectively prevents severe hair loss in breast cancer patients treated with docetaxel and is safe.